

3RD INTERNATIONAL PSYCHOPHARMACOLOGY: DEPRESSION & SCHIZOPHRENIA

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

WELCOME

On behalf of the entire Massachusetts General Hospital Department of Psychiatry, we are proud to welcome you to our conference on International Psychopharmacology.

This international course will be multidisciplinary. It will provide a unique opportunity to understand differing perspectives and approaches from leading mental health experts in the U.S. and Europe. The Massachusetts General Hospital Psychiatry Academy has been hosting the renowned Psychopharmacology Conference in the U.S. for over 40 years.

This three-day conference offers an in-depth review of the latest knowledge in treatment, epidemiology, and diagnosis across mental health conditions including depression and schizophrenia. Our faculty provide a complete update across research developments, assessment tools, barriers to care, and treatment strategies. The agenda is organized into topic-specific modules that include short lectures and Q&A panels. The panels provide the opportunity to ask questions about the content and easily translate evidence into clinical practice.

Enjoy the program!

TARGET AUDIENCE

The target audience for this event is psychiatrists, psychologists, general and family practice physicians, psychiatric nurses, physician assistants, nurse practitioners, and social workers.

EVALUATION FORMS/CME/CEU CERTIFICATES

Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to the **Evaluation and CME Information** document in this syllabus for more information. We strongly encourage you to complete the evaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link to claim credit is as follows:

www.mghcme.org/international

QUESTIONS

Opportunity for questions will be provided at the end of each module during the panel discussion. Please write your questions in the chat box on Zoom. Experience has shown that this method is preferable to that of spontaneous questions.

COPYRIGHT

The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department of Psychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotaping are not allowed. Thank you for your cooperation.



**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

CONTACT INFORMATION

For questions or comments, please contact MGH Psychiatry Academy member services at 866-644-7792 or mghcme@mgh.harvard.edu.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. Identify rational, evidence-based pharmacologic and non-pharmacologic therapies for patients with unipolar, bipolar, and treatment-resistant schizophrenia.
2. Assess obstacles to maintenance of long-term recovery and the liability issues associated with psychopharmacology.
3. Discuss diagnostic and evidenced-based treatment strategies for pediatric onset mood disorders.
4. Compare the newest medications in the pipeline for depression and schizophrenia to those which are currently being used.
5. Discuss the usefulness of well being therapy in depression.
6. Discuss the use of brain stimulation in treatment refractory depression
7. Analyze the evolution of antipsychotic therapy with an emphasis on long acting injectable medication.
8. Compare the neurobiology and evidence-based treatment approaches to schizophrenia and mood disorders.

3RD INTERNATIONAL PSYCHOPHARMACOLOGY: DEPRESSION & SCHIZOPHRENIA

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

McLean Hospital designates this live activity for a maximum of **11.25 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PSYCHOLOGISTS

The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for **11.25** Continuing Education (CE) credits for psychologists.

REGISTERED NURSES

This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for **11.25** contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

SOCIAL WORKERS

This program has been approved for 11 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. NASW-MA Chapter CE Approving Program, Authorization Number D 90236-2.

Other CE Licenses: Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of *AMA PRA Category 1 Credits™* associated with the activity. Providers should check with their regulatory agencies to determine ways in which *AMA PRA Category 1 Credits™* may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents



**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

AGENDA

FRIDAY, MAY 14, 2021

- | | |
|----------------|---|
| 8:30 – 8:35 AM | Welcome Remarks
Maurizio Fava, MD |
| 8:35 – 8:45 AM | Introduction
Maurizio Fava, MD |

MODULE I: CHALLENGES AND OPPORTUNITIES IN THE TREATMENT OF DEPRESSION

- | | |
|---------------------|--|
| 8:45 – 9:30 AM | How do we Differentiate Bipolar from Unipolar Depression?
Andrew Nierenberg, MD |
| 9:30 – 10:15 AM | Depression Sub-Types: Revisiting the Phenomenology of Depression
Maurizio Fava, MD |
| 10:15 – 10:30 AM | Break |
| 10:30 – 11:15 AM | Bipolar Depression: How do we treat it?
Stefano Pallanti, MD, PhD |
| 11:15 – 12:00 PM | Depression: Drug Treatments: What is in the Pipeline?
George Papakostas, MD |
| 12:00 PM – 12:45 PM | Panel Discussion and Q&A
<u>Moderator:</u> Andrew Nierenberg, MD
<u>Panelists:</u> Maurizio Fava, MD & Stefano Pallanti, MD, PhD, George Papakostas, MD |
| 12:45 PM | Adjourn |

SATURDAY, MAY 15, 2021

- | | |
|----------------|--|
| 8:15 – 8:20 AM | Welcome Remarks & Introduction
Maurizio Fava, MD |
|----------------|--|



**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

MODULE II: SPECIAL TOPICS IN DEPRESSION

8:20 – 9:05 AM	Juvenile Forms of Depression Joseph Biederman, MD
9:05 – 9:50 AM	Distinguishing Deficient Emotional Self-Regulation From Mood Disorder Joseph Biederman, MD
9:50 – 10:05 AM	Break
10:05 – 10:50 PM	Well Being Therapy of Depression Giovanni A. Fava, MD
10:50 – 11:35 AM	Role of Neurostimulation in Depression Joan Camprodon, MD, PhD
11:35 – 12:20 PM	Panel Discussion and Q&A <u>Moderator:</u> Maurizio Fava, MD <u>Panelists:</u> Joseph Biederman, MD, Giovanni A. Fava, MD & Joan Camprodon, MD, PhD
12:20 PM	Adjourn

SUNDAY, MAY 16, 2021

8:15 – 8:20 AM	Welcome Remarks & Introduction Maurizio Fava, MD
----------------	--

**MODULE III: SCHIZOPHRENIA AND SCHIZOPHRENIA-RELATED PSYCHOSES: A FOCUS
ON TREATMENT ISSUES**

8:20 – 9:05 AM	Can we Prevent Schizophrenia? Daphne Holt, MD, PhD
9:05 – 9:50 AM	Clinical Approaches to Treatment Resistance in Schizophrenia Oliver Freudenreich, MD, FACLP



**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

9:50 – 10:35 AM	Drug Treatments in Schizophrenia – What is on the Horizon? Siegfried Kasper, MD
10:35 – 10:50 AM	Break
10:50 – 11:35 AM	The Role of Psychosocial Therapies in Schizophrenia Corinne Cather, PhD
11:35 AM – 12:20 PM	Panel Discussion and Q&A <u>Moderator:</u> Oliver Freudenreich, MD, FACLP <u>Panelists:</u> Siegfried Kasper, MD, Daphne Holt, MD, PhD, & Corinne Cather, PhD
12:20 PM	Adjourn

PROGRAM FACULTY

PLANNERS & COURSE DIRECTORS

Maurizio Fava, MD (*Course Director*)

Psychiatrist-in-Chief, Department of Psychiatry
Director, Division of Clinical Research of the MGH Research Institute
Executive Director, Clinical Trials Network & Institute (CTNI)
Massachusetts General Hospital
Associate Dean for Clinical & Translational Research
Slater Family Professor of Psychiatry
Harvard Medical School

Siegfried Kasper, MD (*Course Director*)

Professor Emeritus
Medical University of Vienna
Center for Brain Research



**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

David Rubin, MD (*Course Director*)

Director, Child and Adolescent Psychiatry Residency Training
Massachusetts General Hospital and McLean Hospital
Director, Postgraduate Medical Education, Department of Psychiatry
Executive Director, Massachusetts General Hospital Psychiatry Academy
Massachusetts General Hospital

Jane Pimental, MPH

Managing Director
Massachusetts General Hospital Psychiatry Academy

Susan Sprich, PhD (*Psychologist Reviewer*)

Director, Postgraduate Psychology Education
Director, Cognitive Behavioral Therapy Program
Massachusetts General Hospital
Assistant Professor of Psychology
Harvard Medical School

SPEAKERS

Joseph Biederman, MD

Chief, Clinical & Research Programs in Pediatric Psychopharmacology & Adult ADHD
Director, Bressler Program for Autism Spectrum Disorders
Trustees Endowed Chair in Pediatric Psychopharmacology
Massachusetts General Hospital
Professor of Psychiatry, *Harvard Medical School*

Joan Camprodon, MD, MPH, PhD

Chief, Division of Neuropsychiatry
Director, Laboratory for Neuropsychiatry & Neuromodulation
Director, Transcranial Magnetic Stimulation (TMS) clinical service
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School



**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

Corinne Cather, PhD

Associate Professor of Psychology

Harvard Medical School

Director, Psychological Services of the MGH Schizophrenia Clinical and Research Program

Director, MGH Center of Excellence for Psychosocial and Systemic Research

Giovanni A. Fava, MD

Editor-in-chief, Psychotherapy and Psychosomatics

Clinical Professor of Psychiatry

State University of New York at Buffalo

Oliver Freudenreich, MD, FACLP

Co-Director, MGH Schizophrenia Clinical and Research Program

Massachusetts General Hospital

Associate Professor of Psychiatry

Harvard Medical School

Daphne Holt, MD, PhD

Co-Director, Schizophrenia Clinical and Research Program

Director, Resilience and Prevention Program and Emotion and Social Neuroscience Laboratory

Associate Professor, *Harvard Medical School*

Department of Psychiatry, *Massachusetts General Hospital*

Andrew Nierenberg, MD

Director, Dauten Family Center for Bipolar Innovation

Associate Director, Depression Clinical and Research Program

Director, Clinical Research Support Office and Clinical Research Education Unit

Massachusetts General Hospital

Professor of Psychiatry, *Harvard Medical School*

Stefano Pallanti, MD, PhD

Professor of Psychiatry, *Albert Einstein College of Medicine, New York, USA*

Professor of Psychiatry, *Imperial College, London, UK*

Director, *Istituto di Neuroscienze, Firenze, Italy*

3RD INTERNATIONAL PSYCHOPHARMACOLOGY: DEPRESSION & SCHIZOPHRENIA

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

George Papakostas, MD

Associate Executive Director
Clinical Trials Network and Institute
Massachusetts General Hospital

FACULTY DISCLOSURE STATEMENTS

In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:

Commercial Interest

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial relationships

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant financial relationships

ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “‘relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:

Joseph Biederman, MD

Research Support:

Genentech, Headspace Inc., Lundbeck, Neurocentria Inc., Pfizer, Roche TCRC Inc., Shire Pharmaceuticals Inc., Sunovion, and Tris Tris.

Royalties paid to Department of Psychiatry at MGH (Licensing copyrights rating scale used for ADHD diagnoses):

Biomarin, Bracket Global, Cogstae, Ingenix, Medavent Prophase, Shire, Sunovion, and Theravance

Joan Camprodon, MD, PhD, MPH

Stock (Scientific Advisory Board):

Apex Neuroscience, Hyka Therapeutics

Consult Fee:

Neuronetics

Corrine Cather, PhD

Consult Fee:

Charles River Analytics

Maurizio Fava, MD

Research Support:

Abbott Laboratories; Acadia Pharmaceuticals; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; AXSOME Therapeutics; Biohaven; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Cerecor; Clarus Funds; Clexio Biosciences; Clintara, LLC; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; FORUM Pharmaceuticals; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; Indivior; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; Marinus Pharmaceuticals; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Coordinating Center for Integrated Medicine (NiiCM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; NeuroRx; Novartis AG; Organon Pharmaceuticals; Otsuka Pharmaceutical Development, Inc.; PamLab, LLC; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.;

3RD INTERNATIONAL PSYCHOPHARMACOLOGY: DEPRESSION & SCHIZOPHRENIA

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

Pharmavite® LLC; PharmorX Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shenox Pharmaceuticals, LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Taisho Pharmaceuticals; Takeda Pharmaceuticals; Tal Medical; VistaGen; Wyeth-Ayerst Laboratories

Advisory Board/ Consultant:

Abbott Laboratories; Acadia; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Best Practice Project Management, Inc.; Biogen; BioMarin Pharmaceuticals, Inc.; BioXcel Therapeutics; Biovail Corporation; Boehringer Ingelheim; Boston Pharmaceuticals; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; Clexio Biosciences; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; Indivior; i3 Innovus/Ingenis; Intracellular; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; Marinus Pharmaceuticals; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Navitor Pharmaceuticals, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Osmotica; Otsuka Pharmaceuticals; PamLab, LLC.; Perception Neuroscience; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmorX Therapeutics; Polaris Partners; Praxis Precision Medicines; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; PPD; PThera, LLC; Purdue Pharma; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Relmada Therapeutics, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Shenox Pharmaceuticals, LLC; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Taisho Pharmaceuticals; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex; Teva Pharmaceuticals; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Usona Institute, Inc.; Vanda Pharmaceuticals, Inc.; Versant Venture Management, LLC; VistaGen

Speaking/Publishing:

Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH

**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource, Corp.; Wyeth-Ayerst Laboratories.

Equity Holdings:

Compellis; Psy Therapeutics

Royalty/patent, other income:

Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven. Patents for pharmacogenomics of Depression Treatment with Folate (US_9546401, US_9540691).

Copyright: for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; Wolters Kluwer; World Scientific Publishing Co. Pte.Ltd.

Oliver Freudenreich, MD, FACP

Research Grant:

Avanir, Neurocrine, Janssen, Alkermes

Consultant Fee:

Avanir, Neurocrine, Janssen, Alkermes

Honoraria:

Global Medical Education, Novartis, Otsuka, Roche, Integral

Royalties:

Wolters-Kluwer, UpToDate, Elsevier, MedScape, Springer, Verlag, American Psychiatric Association

Siegfried Kasper, MD

Grants & Research Support:

Janssen Cilag Pharma GmbH, Lundbeck A/S, Schwabe

Consulting Fees and/or Speaker Honoraria:

Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda

Andrew Nierenberg, MD

Consulting Fee/Speaker Honoraria:

Alkermes, Jazz Pharma, Sage Pharma, Otsuka, Neuronetics, Acadia Pharm, EsaiMyriad, Sunovion, Neurostar, Merck Ginger, Protogenics, Neurogenics, and Clexio



**3RD INTERNATIONAL PSYCHOPHARMACOLOGY:
DEPRESSION & SCHIZOPHRENIA**

INTERNATIONAL PERSPECTIVES ON GLOBAL DISORDERS

Friday – Sunday • May 14-16, 2021 • Virtual

Stefano Pallanti, MD, PhD

Speaker/Speaker Fee:

Recordati, Sage, Octapharma

George Papakostas, MD

Honoraria (consulting, roundtable):

Otsuka

Susan Sprich, PhD (Psychologist Reviewer)

Royalties (co-authoring treatment manual and client workbook):

Oxford University Press

Royalties (editing book):

Springer

Honorarium (for serving as one of the Associate Editors of the journal entitled “Cognitive and Behavioral Practice”):

Association for Behavioral and Cognitive Therapies (ABCT)

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.